Shanghai's Hutchison MediPharma Could Close Licensing Deal On Innovative New Crohn's Disease Treatment; Spin-off Likely

BEIJING - The Shanghai-based Hutchison MediPharma, in the ranks of elite Chinese firms aiming to develop innovative medicines, is likely to sign a licensing agreement on its most promising pipeline drug; the deal would mark a major turning point in the outfit's earnings and its future